MP Advisors, Jan 2011, Pages: 391
and a lack of new blockbuster drugs. There are signs of improvement, with the outcome of new clinical trials and new launches expected to reshape market dynamics.
MP Advisor analysts have studied 200 clinical
Datamonitor, Oct 2010, Pages: 196
of innovative products will impact Sanofi Pasteur’s leading position
Opportunities: novel early-stage candidates hold blockbuster potential
Threats: lack of adjuvants may compromise leadership
Datamonitor, Dec 2008, Pages: 267
Introduction
Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products
Success Stories Media, Feb 2012
management problems.
Foreign companies in many cases are the ones forcing change in Japan through their leadership and new (for Japan) management approaches. Success Stories: Japan is the only for-profit
